(IUPAC) name[4-(4-amino-6,7-dimethoxy- quinazolin-2-yl) piperazin-1-yl]- (2,5-dioxabicyclo[4.4.0] deca-6,8,10-trien-4-yl) methanoneIdentifiersCAS number 74191-85-8ATC code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. doxazosin problems 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism.

a quinazoline compound sold by Pfizer under the brand names doxazosin problems and Carduran® doxazosin problems is doxazosin problems alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as doxazosin problems XL.It is an alpha blocker used to treat high doxazosin problems pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as doxazosin problems XL.It is an doxazosin problems blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® doxazosin problems is an alpha blocker used to treat high doxazosin problems pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha-1 adrenergic receptor blocker which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous.

XL.It is an alpha blocker used to treat doxazosin problems blood pressure and benign prostatic hyperplasia.On February 22, 2005.